Skip to main content
Signal8

Schoch Charles

SEC insider (Form 3/4/5 filer). CIK 0002007349. Chief Financial Officer at Candel Therapeutics, Inc. (CADL). 7 reported Form 4/5 transactions since Sep 2024; latest on Jan 26, 2026. Located in NEEDHAM, MA.

Companies Schoch Charles has filed insider reports for

  • Candel Therapeutics, Inc. (CADL): Officer, Chief Financial Officer
Schoch Charles profile photo

Schoch Charles

CIK: 0002007349

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (42.9%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (57.1%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Candel Therapeutics, Inc. logo
CADL

Candel Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

  • Candel Therapeutics, Inc. logo
    CADL

    Candel Therapeutics, Inc.

    Jan 26, 2026
    Award

    Stock Option (Right to Buy)

    Direct
    232K shares-
  • Candel Therapeutics, Inc. logo
    CADL

    Candel Therapeutics, Inc.

    Jun 25, 2025
    Award
    Direct
    5.4K shares at avg. $4.67$25K
  • Candel Therapeutics, Inc. logo
    CADL

    Candel Therapeutics, Inc.

    Jun 20, 2025
    Award

    Stock Option (Right to Buy)

    Direct
    50K shares-
  • Candel Therapeutics, Inc. logo
    CADL

    Candel Therapeutics, Inc.

    Mar 17, 2025
    Sale
    Direct
    5K shares at avg. $8.83$44K
  • Candel Therapeutics, Inc. logo
    CADL

    Candel Therapeutics, Inc.

    Feb 12, 2025
    Award

    Stock Option (Right to Buy)

    Direct
    83K shares-
  • Candel Therapeutics, Inc. logo
    CADL

    Candel Therapeutics, Inc.

    Jan 15, 2025
    Sale
    Direct
    9.5K shares at avg. $7.22$69K
  • Candel Therapeutics, Inc. logo
    CADL

    Candel Therapeutics, Inc.

    Jan 8, 2025
    Sale
    Direct
    10K shares at avg. $8.22$82K

1-7 of 7